Do razzle-dazzle health care ETFs disguise weakness? For many investors in exchange traded funds, that's a real concern. The sector is handily beating its peers -- as it has for several years. IBD Leaderboard stocks Illumina (ILMN) and Mallinckrodt (MNK) show that biotech and pharma stocks still have oomph. Institutional buyers are piling into names both well-known (Actavis (ACT) and under-the-radar (Diplomat Pharmacy (DPLO), a recent IPO). But
Wednesday 10 June 2015
Can Health Care ETFs Keep Beating The Stock Market?
Otmane El Rhazi from Investor's Business Daily - ETFs RSS.
Do razzle-dazzle health care ETFs disguise weakness? For many investors in exchange traded funds, that's a real concern. The sector is handily beating its peers -- as it has for several years. IBD Leaderboard stocks Illumina (ILMN) and Mallinckrodt (MNK) show that biotech and pharma stocks still have oomph. Institutional buyers are piling into names both well-known (Actavis (ACT) and under-the-radar (Diplomat Pharmacy (DPLO), a recent IPO). But
Do razzle-dazzle health care ETFs disguise weakness? For many investors in exchange traded funds, that's a real concern. The sector is handily beating its peers -- as it has for several years. IBD Leaderboard stocks Illumina (ILMN) and Mallinckrodt (MNK) show that biotech and pharma stocks still have oomph. Institutional buyers are piling into names both well-known (Actavis (ACT) and under-the-radar (Diplomat Pharmacy (DPLO), a recent IPO). But
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment